Leukocyte Adhesion Deficiency Type II – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Leukocyte adhesion deficiency type II (LAD-II) is a form of LAD characterized by recurrent bacterial infections, severe growth delay, and severe intellectual deficit. LAD-II is a carbohydrate-deficient glycoprotein syndrome (CDG syndrome) and is therefore also referred to as CDG IIc. It results from mutations in the SLC35C1 gene (11p11.2), encoding the guanosine 5'-diphosphate (GDP)-fucose transporter localized in the Golgi apparatus. This is a specific fucose transporter that translocates GDP-fucose from the cytosol to the Golgi, where it is used as a substrate for fucosylation. Thelansis’s “Leukocyte Adhesion Deficiency Type II Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leukocyte Ad...